ArticleFrontiers in immunology2018
Interplay of DDP4 and IP-10 as a Potential Mechanism for Cell Recruitment to Tuberculosis Lesions.
Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 50 citations in OpenAlex.
- Epitope-specific airway-resident CD4+ T cell dynamics during experimental human RSV infection.The Journal of clinical investigation · 2020Trial
- A quadral biosignature of IFN-γ, IL-2, IL-12 and IP-10 increases the diagnostic potential for latent tuberculosis among diabetic patients in Uganda.BMC immunology · 2025Article
- Target trial emulation of DPP-4 Inhibitors in patients with T2DM for pulmonary tuberculosis: a nationwide observational data.BMC medicine · 2025Observational
- Host-protein biomarkers distinguish asymptomatic TB in an active case finding study.IJTLD open · 2025Article
- Metabolic dysfunction impairs Mycobacterium tuberculosis-specific cytokine and chemokine responses in latent tuberculosis and type 2 diabetes mellitus.Scientific reports · 2025Article
- Article
- Multiple cytokine analysis based on QuantiFERON-TB gold plus in different tuberculosis infection status: an exploratory study.BMC infectious diseases · 2024Article
- Combined analysis of host IFN-γ, IL-2 and IP-10 as potential LTBI biomarkers in ESAT-6/CFP-10 stimulated blood.Frontiers in molecular medicine · 2024Article
- Article
- Host biomarker-based quantitative rapid tests for detection and treatment monitoring of tuberculosis and COVID-19.iScience · 2023Article
- Response to Hypoxia and the Ensuing Dysregulation of Inflammation ImpactsAmerican journal of respiratory and critical care medicine · 2022Article
- Study on the Correlation between Interleukin-27 and CXCL10 in Pulmonary Tuberculosis.Journal of immunology research · 2022Article
- Elevated IP-10 at the Protein and Gene Level Associates With Pulmonary TB.Frontiers in cellular and infection microbiology · 2022Article
- CXC Chemokines in the Pathogenesis of Pulmonary Disease and Pharmacological Relevance.International journal of inflammation · 2022Review
- Eosinophils are part of the granulocyte response in tuberculosis and promote host resistance in mice.The Journal of experimental medicine · 2021Article
- Therapeutic Response and Possible Biomarkers in Acute Attacks of Neuromyelitis Optica Spectrum Disorders: A Prospective Observational Study.Frontiers in immunology · 2021Observational
- Effect of Inflammatory Cytokines/Chemokines on Pulmonary Tuberculosis Culture Conversion and Disease Severity in HIV-Infected and -Uninfected Individuals From South Africa.Frontiers in immunology · 2021Article
- GM-CSF and IL-33 Orchestrate Polynucleation and Polyploidy of Resident Murine Alveolar Macrophages in a Murine Model of Allergic Asthma.International journal of molecular sciences · 2020Article
- Glucocorticoids mobilize macrophages by transcriptionally up-regulating the exopeptidase DPP4.The Journal of biological chemistry · 2020Article
- BCG and BCGΔBCG1419c protect type 2 diabetic mice against tuberculosis via different participation of T and B lymphocytes, dendritic cells and pro-inflammatory cytokines.NPJ vaccines · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introduction
resultsWe measured plasma levels of agonist and antagonist CXCL10 by Simoa digital ELISA, as well as DPP4 enzyme activity in the plasma of 20 patients with active TB infection, 10 patients with pneumonia infection, and a group of 10 healthy controls. We found higher levels of total and antagonist CXCL10 and reduced DPP4 enzyme activity in the plasma of TB patients compared to controls. We traced the source of CXCL10 secretion using immunohistochemical and confocal analysis to multinucleated giant cells in the TB lesions, and variable expression by macrophages. Interestingly, these cells were associated with DPP4-positive T cells. Moreover, the analysis of lymphocytes at the site of TB infection (bronchoalveolar lavage) showed a reduced frequency of CXCR3
interpretationOur data suggests that CXCL10 antagonism may be an important regulatory mechanism occurring at the site of TB pathology. CXCL10 can be inactivated shortly after secretion by membrane bound DPP4 (CD26), therefore, reducing its chemotactic potential. Given the importance of Th1 cell functions and IFN-γ-mediated effects in TB, our data suggest a possible unappreciated regulatory role of DPP4 in TB. PERSPECTIVES: DPP4 is the target for a class of enzyme inhibitors used in the treatment of diabetes, and the results from this study suggest that these drugs could be repurposed as an adjunct immunotherapy of patients with TB and MDR-TB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.